Press release

Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics

Sponsored by Businesswire

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced a new collaboration with
Pandion Therapeutics, to apply its antibody optimization platform to the
targeting arm of a bispecific antibody. Pandion Therapeutics is a
biotechnology platform company developing therapeutics to achieve
localized immunomodulation to treat autoimmune and inflammatory disease.

“Twist Bioscience, through its Biopharma division, has a highly
differentiated capability to optimize antibodies for many attributes
including affinity, expression, solubility, half-life, immunogenicity,
druggability and processability,” said Anthony Coyle, Ph.D., co-founder
and CEO of Pandion. “We look forward to this initial project on a key
therapeutic target that may offer hope for patients in need of new
treatment options.”

“By approaching autoimmune and inflammatory disease through antibody
therapeutics acting locally at the disease site, Pandion is working to
change the trajectory of treatment,” commented Emily M. Leproust, Ph.D.,
CEO and co-founder of Twist Bioscience. “Using our state-of-the-art
antibody optimization platform, we look forward to partnering with
Pandion to provide enhanced antibodies ideally suited to the human body
to potentially improve patient outcomes.”

About Pandion Therapeutics

 is a biotechnology company developing a pipeline of
antibody therapeutics to achieve localized immunomodulation for
autoimmune and inflammatory diseases and transplantation. The company’s
proprietary technology platform enables the design of bispecific
antibodies with targeting fragments that bind to specific tissues at the
local site of inflammatory disease, coupled with effector molecules that
modulate immune activity to restore immune homeostasis.

Pandion was founded in 2017 and closed a $58M Series A financing round
in early 2018 with funding from Polaris Partners, Versant Ventures,
Roche Venture Fund, SR One and BioInnovation Capital. The company is
headquartered in Cambridge, Massachusetts. Please visit

About Twist
Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Follow us on Twitter
| Facebook
| LinkedIn
| YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, the potential promise of Twist Bioscience’s antibody
optimization platform to improve therapeutic efficacy. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the risks and
uncertainties of the ability to attract new customers and retain and
grow sales from existing customers; risks and uncertainties of rapidly
changing technologies and extensive competition in synthetic biology
could make the products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of a significant
customer; risks of third party claims alleging infringement of patents
and proprietary rights or seeking to invalidate Twist Bioscience’s
patents or proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies. For
a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s business in
general, see Twist Bioscience’s risk factors set forth in Twist
Bioscience’s Annual Report on Form 10-K filed with the Securities and
Exchange Commission on December 20, 2018 and Twist Bioscience’s Form
10-Q for the quarter ended December 31, 2018 filed with the Securities
and Exchange Commission on February 11, 2019. Any forward-looking
statements contained in this press release speak only as of the date
hereof, and Twist Bioscience specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.